2022
The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma
Sher L, Passalacqua G, Taillé C, Cohn L, Daizadeh N, Pandit-Abid N, Soler X, Khodzhayev A, Jacob-Nara J, Deniz Y, Rowe P, Nag A, Zhang Y. The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma. Annals Of Allergy Asthma & Immunology 2022, 130: 298-304. PMID: 36509407, DOI: 10.1016/j.anai.2022.12.002.Peer-Reviewed Original ResearchConceptsPlacebo-treated patientsSevere asthmaActivity limitationsDose reductionAQLQ scoresDupilumab groupWeek 24Open-label extensionProportion of patientsType 2 inflammationHuman monoclonal antibodyQuality of lifeOral corticosteroidsOCS useInterleukin-4Long-term effectsAsthmaPatientsSymptomsMonoclonal antibodiesSleepReceptor componentsDupilumabDyspneaWeeksPOSB359 Effect of Dupilumab on Physical and Work-Related Activity in Patients with Moderate-to-Severe Asthma: Liberty Asthma QUEST
Sher L, Taillé C, Cohn L, Quirce S, Daizadeh N, Pandit-Abid N, Ortiz B, Nag A, Zhang Y. POSB359 Effect of Dupilumab on Physical and Work-Related Activity in Patients with Moderate-to-Severe Asthma: Liberty Asthma QUEST. Value In Health 2022, 25: s230. DOI: 10.1016/j.jval.2021.11.1126.Peer-Reviewed Original Research
2021
REAL-WORLD EFFECTIVENESS OF DUPILUMAB ON PATIENT-REPORTED OUTCOMES AND SYMPTOMS IN ASTHMA: 3-MONTH FOLLOW-UP DATA FROM RESPIRE, AN OBSERVATIONAL STUDY WITH PATIENTS RECRUITED FROM A US DUPILUMAB PATIENT SUPPORT PROGRAM
Cohn L, Zhang Y, Wang J, Chen C, Ortiz B, Djandji M, Zhang S, Yang M, Zeiger R. REAL-WORLD EFFECTIVENESS OF DUPILUMAB ON PATIENT-REPORTED OUTCOMES AND SYMPTOMS IN ASTHMA: 3-MONTH FOLLOW-UP DATA FROM RESPIRE, AN OBSERVATIONAL STUDY WITH PATIENTS RECRUITED FROM A US DUPILUMAB PATIENT SUPPORT PROGRAM. CHEST Journal 2021, 160: a29-a30. DOI: 10.1016/j.chest.2021.07.075.Peer-Reviewed Original Research
2011
IFN-γ Acts on the Airway Epithelium To Inhibit Local and Systemic Pathology in Allergic Airway Disease
Mitchell C, Provost K, Niu N, Homer R, Cohn L. IFN-γ Acts on the Airway Epithelium To Inhibit Local and Systemic Pathology in Allergic Airway Disease. The Journal Of Immunology 2011, 187: 3815-3820. PMID: 21873527, PMCID: PMC3178669, DOI: 10.4049/jimmunol.1100436.Peer-Reviewed Original ResearchConceptsAirway epitheliumAllergic airway inflammationAllergic airway diseaseTh2 cell activationGoal of therapyProduction of IFNAdministration of medicationsSystemic side effectsAirway mucosal surfaceAirway epithelial cellsSites of inflammationIFN-γ actionAirway inflammationAirway obstructionPersistent asthmaRefractory asthmaAirway diseaseIFN-γRTh1 cellsPathological responseSystemic pathologyEffector functionsSide effectsBone marrowAsthma
2004
Asthma: Mechanisms of Disease Persistence and Progression
Cohn L, Elias JA, Chupp GL. Asthma: Mechanisms of Disease Persistence and Progression. Annual Review Of Immunology 2004, 22: 789-815. PMID: 15032597, DOI: 10.1146/annurev.immunol.22.012703.104716.BooksConceptsIL-13Key effector cytokineAnti-inflammatory therapyIL-13 productionProduction of chemokinesProgression of diseaseAirway fibrosisAllergic asthmaAirway remodelingEffector cytokinesEosinophilic inflammationPersistent diseaseTh2 cytokinesEpithelial damageDisease progressionInflammatory responseTh2 cellsMucus productionSmooth muscleBronchial airwaysMatrix metalloproteinasesAnimal dataAsthmaDisease persistenceInflammation
2002
Recent Concepts in the Pathogenesis and Treatment of Asthma
Whittaker L, Cohn L. Recent Concepts in the Pathogenesis and Treatment of Asthma. Clinical Pulmonary Medicine 2002, 9: 135-144. DOI: 10.1097/00045413-200205000-00001.Peer-Reviewed Original ResearchTreatment of asthmaLow-dose antigen exposureCD4 lymphocyte subsetsSpecific proinflammatory mediatorsMainstay of therapyAirways of asthmaticsPathogenesis of asthmaAirway hyperresponsivenessAirflow obstructionLymphocyte subsetsMucus hypersecretionAntigen exposureProinflammatory mediatorsInflammatory cytokinesTh2 lymphocytesTh1 cellsCellular inflammationCommon syndromeNovel therapiesAsthmaDisease processInflammationPathogenesisΒ-agonistsContinued investigation
2000
T-helper type 2 cell-directed therapy for asthma
Cohn L, Ray A. T-helper type 2 cell-directed therapy for asthma. Pharmacology & Therapeutics 2000, 88: 187-196. PMID: 11150597, DOI: 10.1016/s0163-7258(00)00091-7.BooksConceptsTh2 cell differentiationT helper type 2 cellsNew immunomodulatory strategiesCell-directed therapiesChronic inflammatory diseaseTh2 cell functionType 2 cellsTh cell developmentImmunomodulatory strategiesPathophysiologic abnormalitiesInflammatory diseasesRespiratory tractTh2 cellsImmune responseTraditional therapiesCell differentiationBronchial airwaysAsthmaTherapyCell functionCell effectsCytokinesDiseaseCell developmentMolecular mechanisms
1999
Inhibition of Allergic Inflammation in a Murine Model of Asthma by Expression of a Dominant-Negative Mutant of GATA-3
Zhang D, Yang L, Cohn L, Parkyn L, Homer R, Ray P, Ray A. Inhibition of Allergic Inflammation in a Murine Model of Asthma by Expression of a Dominant-Negative Mutant of GATA-3. Immunity 1999, 11: 473-482. PMID: 10549629, DOI: 10.1016/s1074-7613(00)80122-3.Peer-Reviewed Original ResearchMeSH KeywordsAerosolsAmino Acid SubstitutionAnimalsAsthmaBronchoalveolar Lavage FluidDNA-Binding ProteinsDrug HypersensitivityEosinophiliaGATA3 Transcription FactorGene Expression RegulationGenes, DominantImmunizationImmunoglobulin EInflammationInterleukin-13Interleukin-4Interleukin-5LungMiceMice, Inbred C57BLMice, TransgenicMucusMutagenesis, Site-DirectedOvalbuminTh2 CellsTrans-ActivatorsConceptsCytokines IL-4GATA-3IL-13IL-4IL-5Th2 cytokines IL-4Pathogenesis of asthmaTreatment of asthmaTranscription factor GATA-3Potential therapeutic targetAirway eosinophiliaTh2 responsesAllergic inflammationAllergic diseasesTh2 cytokinesT-cell-specific fashionTh1 cellsIgE synthesisTh2 cellsMucus productionMurine modelTherapeutic targetTransgenic miceAsthmaDominant negative mutant